BioSpace News Archive

Volastra Therapeutics, a clinical-stage cancer biotechnology company, today announced the appointment of David Nicholson, Ph.D., as an independent member of its Board of Directors.

MaaT Pharma announced that the first patient has been treated as part of its Phase 2b trial, called PHOEBUS, investigating the efficacy of MaaT033 in improving overall survival at 12 months for patients with blood cancer receiving allo-HSCT.

BioCina Pty Ltd. announced the expansion of their partnership with GPN Vaccines Ltd. GPN Vaccines is a biotechnology company developing a proprietary engineered whole-cell vaccine called Gamma-PN™ against Streptococcus pneumoniae.

Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery, announced the appointment of Hazel Jones as Chief Operating Officer.

Recently, the results of the Phase I study for iparomlimab, developed by Qilu Pharmaceutical Co., Ltd. were published online in the academic journal Frontiers in Immunology.

Fennec Pharmaceuticals Inc., a commercial stage specialty pharmaceutical company, reported its financial results for the third quarter ended September 30, 2023 and provided a business update.

First handheld polymerase chain reaction (PCR) genomic diagnostic cartridge and chip to transform real-time decision support for healthy lifestyle choices and potential to transform the diagnosis of infections and cancer risk based on personal genomics at point-of-decision NantNudge close multi-million dollar deal with Imperial College spin-off, DnaNudge First soft launch in Los Angeles at the Inspirational Women Forum conference on November 7, 2023.

MannKind Corporation announced that it has fully enrolled patients in INHALE-3, a Phase 4 clinical trial evaluating inhaled insulin versus usual care in adults living with type 1 diabetes.

VolitionRx Limited, a multi-national epigenetics company, and Veterinary Pathology Group, a leading high quality diagnostic laboratory, have joined forces to launch the Nu.Q® Vet Cancer Test to veterinary practices in the UK and Ireland.

BioNTech SE reported financial results for the three and nine months ended September 30, 2023, and provided an update on its corporate progress.